Pfizer-BioNTech begin late-stage study of lead COVID-19 vaccine candidate

Title:
Pfizer-BioNTech begin late-stage study of lead COVID-19 vaccine candidate

Authors:
Vishwadha Chander & Carl O'Donnell

Publsihed:
Reuters, 28 July 2020
https://www.reuters.com/article/us-health-coronavirus-pfizer-biontech/pfizer-biontech-begin-late-stage-study-of-lead-covid-19-vaccine-candidate-idUSKCN24S2Q9

From the article:
German biotech BioNTech and U.S. drugmaker Pfizer Inc said on Monday they would begin a pivotal global study to evaluate their lead COVID-19 vaccine candidate.

University of Oxford & AstraZeneca - Oxford-AstraZeneca Covid vaccine study shows dual immune action

Title:
Oxford-AstraZeneca Covid vaccine study shows dual immune action

By:
Bloomberg

Published:
Maverick Citizen, 20 July 2020
https://www.dailymaverick.co.za/article/2020-07-20-oxford-astrazeneca-covid-vaccine-study-shows-dual-immune-action/#gsc.tab=0

From the article:
A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, a sign of progress in the high-stakes pursuit of a shot to defeat the pathogen.

The University of the Witwatersrand (Wits) - Wits announces SA's first Covid-19 vaccine trial, first participants to be enrolled this week

Title:
Wits announces SA's first Covid-19 vaccine trial, first participants to be enrolled this week

Author:
Canny Maphanga

Published:
News24, 23 June 2020
https://www.news24.com/news24/southafrica/news/just-in-wits-announces-sas-first-covid-19-vaccine-trial-first-participants-to-be-enrolled-this-week-20200623

Key points from the article:
* Wits university announces SA's first Covid-19 vaccine trial, with participants enrolling this week.
* This comes as the country breaches 100 000 cases of Covid-19.
* Participants are to be divided in three groups - two groups include HIV-negative participants and one group includes people living with HIV.